tiprankstipranks
Trending News
More News >

Orthocell Expands into Thai Market with Remplir™ Approval

Story Highlights
Orthocell Expands into Thai Market with Remplir™ Approval

Confident Investing Starts Here:

Orthocell Ltd ( (AU:OCC) ) has provided an update.

Orthocell Ltd has received regulatory approval from the Thai FDA to commence sales of its nerve repair product Remplir™ in Thailand, a market valued at US$84 million. This approval, achieved through an expedited registration pathway, significantly enhances Orthocell’s presence in the Asia Pacific region and is expected to drive revenue growth. The company plans to partner with a local distributor and anticipates first sales in the second half of 2025. With a strong cash reserve and no debt, Orthocell is well-positioned to expand its global footprint and capitalize on the growing demand for nerve repair solutions.

More about Orthocell Ltd

Orthocell Ltd is a regenerative medicine company based in Perth, Australia. The company specializes in developing and commercializing products for the repair and regeneration of damaged nerves, with its flagship product being Remplir™, a collagen wrap used in nerve repair surgery. Orthocell operates in a global market with approvals in the US, Australia, New Zealand, Singapore, and now Thailand, targeting a large addressable nerve repair market.

YTD Price Performance: -4.80%

Average Trading Volume: 1,556,206

Technical Sentiment Signal: Sell

Current Market Cap: A$312.1M

Learn more about OCC stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App